Dosage forms and method for ameliorating male erectile dysfunction

Patent 5770606 Issued on June 23, 1998. Estimated Expiration Date:

October 20, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

2818855

Method of effecting and enhancing an erection
Patent #: 4127118
Issued on: 11/28/1978
Inventor: Latorre

Treatment of sexual dysfunction
Patent #: 4521421
Issued on: 06/04/1985
Inventor: Foreman

(-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
Patent #: 4543256
Issued on: 09/24/1985
Inventor: Neumeyer

(+)-N-N-propylnorapomorphine and selective limbic activity
Patent #: 4687773
Issued on: 08/18/1987
Inventor: Neumeyer , et al.

Pharmaceutical preparations containing cyclodextrin derivatives
Patent #: 4727064
Issued on: 02/23/1988
Inventor: Pitha

Impotence ointment
Patent #: 4801587
Issued on: 01/31/1989
Inventor: Voss , et al.

Urethral insert for treatment of erectile dysfunction
Patent #: 5242391
Issued on: 09/07/1993
Inventor: Place, et al.

Method of treating impotence Patent #: 5270323
Issued on: 12/14/1993
Inventor: Milne, Jr., et al.

Inventors

Assignee

Application

No. 546498 filed on 10/20/1995

US Classes:

514/284Tetracyclo ring system having the six-membered hetero ring as one of the cyclos

Examiners

Primary: Jarvis, William R. A.

Attorney, Agent or Firm

Olson & Hierl, Ltd.

Foreign Patent References

0579 435 EP. 01/13/1994
WO-A-94 22445 WO. 10/13/1994

International Class

A61K 031/44

Abstract

Psychogenic impotence or erectile dysfunction can be identified in psychogenic male patients and can be ameliorated, without substantial undesirable side effects, by sublingual administration of apomorphine dosage forms so as to maintain a plasma concentration of apomorphine of no more than about 5.5 nanograms per milliliter.

Other References

Tagliamonte et al., Pharm. Biochem. and Behavior 2:257 (1974)
Laudron et al., Biochem. Pharmacology 28:2161-2165 (1979)
Baldessarini et al., in Gessa et al., eds., Apomorphine & Other Dopaminomimetics, vol. 1: Basic Pharmacology, Raven Press, N.Y. (1981), pp. 219-228
Lal et al., J. Neural. Transmission 54:75-84 (1982)
Gower et al., European J. Pharmacology 122:239-244 (1986)
Segraves et al., Arch. Sexual Behav. 16(2):125-137 (1987)
Melis et al., Brain Research 415:98-104 (1987)
Lal, Prog. Neuro-Psychopharm. & Biol. Psych. 12:117-164 (1988)
Pehek et al., Pharm. Biochem. and Behavior 31:201-208 (1988)
Danjou et al., Br. J. Clin. Pharmac. 26:733-739 (1988)
Gancher et al., Ann. Neurol. 26:232-238 (1989)
Danjou et al., J. Pharmacol. Methods 21:61-69 (1989)
Segraves, Arch. Gen. Psych. 46:275-284 (1989)
Panegyres et al., Med. J. Australia 155:371-374 (1991)
Lal et al., J. Psych. Neurosci. 16(5):262-266 (1991)
Heaton et al., J. Urology 145:1099-1102 (1991)
Montastruc et al., Clin. Neuropharmacology 14(5):432-437 (1991)
Durif et al., Eur. J. Clin. Pharmacology 41:493-494 (1991)
Gancher et al., Movement Disorders 6(3):212-216 (1991)
Essink et al., J. Chromatography 570:419-424 (1991)
Segraves et al., J. Urology 145:1174-1175 (1991)
Durif et al., Clinical Neuropharmacology, 16(2):157-166 (1993)
Seagraves, R.T., Dopamine agonists and their effect on the human penile erectile response, pp. 225-229 in Bancroft, J., editor, The Pharmacology of Sexual Function and Dysfunction, Excerpta Medica, Amsterdam (1995